Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424066 | 1.00 | AKR1C3 (0.33) | AKR1C3AKR1C2PTGS2PTGS1MEN1 | |
| SCHEMBL6464204 | 0.92 | AKR1C3 (0.34) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL6467258 | 0.92 | AKR1C3 (0.34) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL6425619 | 0.92 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGS2PTGS1PPARG | |
| SCHEMBL6424959 | 0.92 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGS2PTGS1PPARG | |
| SCHEMBL6425806 | 0.91 | AKR1C3 (0.35) | AKR1C3AKR1C2PTGS2PTGS1MEN1 | |
| SCHEMBL6425967 | 0.91 | AKR1C3 (0.36) | AKR1C3AKR1C2PTGS2PTGS1MEN1 | |
| SCHEMBL6424935 | 0.91 | AKR1C3 (0.36) | AKR1C3AKR1C2PTGS2PTGS1MEN1 | |
| SCHEMBL6424393 | 0.90 | AKR1C3 (0.34) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL6425205 | 0.90 | AKR1C3 (0.34) | AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885PTGS2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.